lyka labs | Business Upturn

Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain

Aman Shukla — Tue, 08 Apr 2025 06:00:49 +0000

Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitment to advancing topical drug delivery systems and pharmaceutical innovation.

Pregabalin Gel 8% is a breakthrough formulation for the localized treatment of diabetic neuropathic pain, offering targeted relief with minimal systemic side effects compared to traditional oral medications. Approved by the Central Drugs Standard Control Organization (CDSCO) in October 2024, the product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P licensing agreement.

As the first-of-its-kind topical pregabalin formulation in India, this gel represents a major step forward in pain management. Lyka Labs’ clinical studies demonstrate the gel’s efficacy, safety, and ease of use, making it a promising solution for millions of patients suffering from chronic diabetic neuropathic pain.

The patent not only enhances Lyka Labs’ intellectual property portfolio but also reinforces its mission to provide innovative pharmaceutical solutions. With a strong focus on patient-centric therapies, Lyka continues to lead in developing effective and safe alternatives for chronic conditions.

Stock to Watch Today: Lyka Labs receives CDSCO approval to manufacture and market Pregabalin Gel for neuropathic pain

Aditya Bhagchandani — Tue, 15 Oct 2024 02:31:14 +0000

Lyka Labs received product permission from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Pregabalin Gel 8% in India. The gel is used for the treatment of neuropathic pain, marking a significant addition to the company’s product portfolio.

This new topical treatment, designed to relieve Diabetic Neuropathic Pain (DNP), represents a significant advancement in managing diabetes-related neuropathy in India, where diabetes cases have surged.

Clinical trials have demonstrated that the treatment is effective and well-tolerated, with fewer side effects compared to oral Pregabalin, marking a promising development for Lyka Labs.

Lyka Labs, a pharmaceutical company specializing in sterile and topical preparations, is actively advancing its research at its R&D Centre in Mumbai. The company is focused on developing a wide range of new formulations and drug delivery systems, particularly in the areas of Lyophilized Injectables and Topical Preparations.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Lyka Labs receives CDSCO approval to manufacture and market Pregabalin Gel 8% w/w in India

Aman Shukla — Mon, 14 Oct 2024 12:28:00 +0000

Lyka Labs has obtained CDSCO approval to manufacture and market Pregabalin Gel 8% w/w in India. This novel topical treatment, aimed at alleviating Diabetic Neuropathic Pain (DNP), marks a crucial step forward in the management of diabetes-related neuropathy in India, where the prevalence of diabetes has risen dramatically.

Clinical trials showed that it is effective and well-tolerated, with fewer side effects than oral Pregabalin. This might be a great step for Lyka Labs.

Lyka is a pharmaceutical firm with a specialization in sterile and topical preparations. Lyka’s R&D Centre in Mumbai is actively developing a wide range of new formulations and drug delivery systems in its focus areas of Lyophilized Injectables and Topical Preparations.

Hulst B V drops 5.52% equity stakes in Coforge

Aayushi Singh — Wed, 04 Aug 2021 19:07:44 +0000

On August 4, the promoter, Hulst B V, had offloaded 5.52 per cent of the equity stake in the IT solutions organisation, Coforge.

On August 4, in the bulk deals data, it was shown that Hulst B V sold over 33.5 lakh equity shares in Coforge, which represented 5.52 per cent of the total paid-up equity, the shares were sold at Rs 4,738.67 per share on the NSE.

As of June 2021, Hulst Bv has held over 55.73 per cent of the equity stake in the company. In the deal, Nomura India Investment Fund, Mother Fund, was the buyer, which had acquired overb3.5 lakh equity shares in the Coforge at Rs 4,710 per share.

BNP Paribas Arbitrage sold over 31,74,056 equity shares in IndiaBulls Housing Finance which were 0.68 per cent of total paid-up equity, the shares were sold at Rs 280.44 per share on the NSE. As of June 2021, the BNP Paribas Arbitrage held a 3.04 per cent stake in the company which are equal to 1,40, 42,887 equity shares.

Among the others deals, Investor Cobra India (Mauritius) had sold over 3,11,595 equity shares at Rs 86.47 per cent in Lyka Labs on the NSE. The investor Cobra India till June 2021, had over 10,04,659 equity shares in Lyka Labs which had a 3.5 per cent stake.